DUBLIN--(BUSINESS WIRE)--The "Global Human Microbiome Modulators Market: Focus on Non-Dairy Supplements, Drugs, Applications, 15 Countries Data, Pipeline Product Mapping, and Competitive Landscape - Analysis and Forecast, 2018-2023" report has been added to ResearchAndMarkets.com's offering.
Global Human Microbiome Modulators Market to Reach $2.79 Billion by 2023
The purpose of the study is to gain a holistic view of the global human microbiome modulators market in terms of various factors influencing the market, including regulatory reforms and technological advancements. The market has been segmented into products, applications, and regions.
Given the fact that in 2015, the global healthcare expenditure was estimated by the World Health Organization (WHO) at approximately $7 trillion, the escalating prevalence of NCDs such as diabetes, obesity, cardiovascular diseases, respiratory diseases, and cancers, among others, have significantly driven this expenditure.
Expected to reach over $8.5 trillion by 2020, the global health expenditure has been one of the leading causes of economic burden over governments, worldwide.
As of WHO's estimates in 2016, NCDs are responsible for almost 71% deaths globally, killing 41 million people each year. Also, WHO's estimates in 2017 report of a global population of 7.55 billion individuals, a recurrent factor in having direct consequences upon increasing the global disease burden.
In addition to the aforementioned estimates, the United Nations Department of Economic and Social Affairs/Population Division estimated that the life expectancy increased from 67.2 years to 70.8 years in the years 2010-2015. In the same report, it was also estimated that approximately 13% of the global population was aged 60 years or above.
Compounding these factors, the global economic, clinical, and social burden of NCDs has been escalating at a rapid pace. Another largely undermined factor for the rising global disease burden is antimicrobial resistance (AMR).
The advent of precision medicine, a patient-centric treatment approach, is perceived to be promising in driving a paradigm shift in the healthcare industry, facilitating the elimination of uncertainty pertaining to trial and error method of medications, and consequently eliminating unnecessary healthcare spending.
Till 2010, the healthcare industry was largely dominated by synthetic drug modules catering to major disease indications. However, post-2010, precision care has been the prime target for any therapeutic module.
The global human microbiome modulators market has been witnessing a steady annual growth rate of approximately 6.08% in past three years (2015-2017), and the market is expected to continue to grow with a double digit CAGR of 16.29% during the forecast period, 2018-2023.
Growing at a CAGR of 13.92% during the forecast period of 2018-2023, the probiotics and creams product segment is anticipated to generate a value of $1.66 billion in 2023. However, the global market for drugs is anticipated to grow at the fastest CAGR of 22.26% during the forecast period 2018-2023.
- Rising Geriatric Population
- Increasing Incidence of Lifestyle-related Diseases
- Gradual Demand for Preventive Medication with Minimal/No Side-Effects
- Limited Success Rate of Drugs Targeting Specific Diseases
- Insufficient Application-Based Research Hindering Market Pull
- Lack of Awareness Regarding the Usage of Probiotics and Prebiotics
- Non-Harmonized Government Regulations on Probiotics and Prebiotics
- Massive Scope for Phenomenal Profits through Venturous Investments
- Integrative Industry-Academia Collaboration
- Rise of Next-Generation Probiotics
- Novel Diagnostic Applications
Key Topics Covered
1 Market Overview
2 Market Dynamics
3 Competitive Landscape
4 Regulatory Framework
5 Global Human Microbiome Modulators Market (by Product)
6 Global Human Microbiome Modulators Market (by Application)
7 Global Human Microbiome Modulators Market (by Region)
8 Company Profiles
- Bayer AG
- BioGaia AB
- Chr. Hansen Holding A/S
- DowDuPont Inc.
- Garden of Life LLC.
- Ingredion Incorporated
- ISOThrive LLC
- Jarrow Formulas Inc.
- Koninklijke DSM N.V.
- MicroBiome Therapeutics LLC
- Lallemand Inc.
- Pharmavite LLC
- Probi AB
- Probiotics International Limited (ADM Protexin)
- Quorum Innovations LLC
- Sanofi S.A.
- The Procter and Gamble Company
- Yakult Honsha Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/5g6jhv/global_human?w=4